AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32711542 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided radioactive RIS implantation
Number of subjects: 66
Study 32711544 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs as biomarkers
Number of subjects: 0
Study 32711544 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Number of subjects: 0
Study 32711544 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in miRNA during surveillance
Number of subjects: 0
Study 32711747 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen exposure (≥33.1% oxygen)
Number of subjects: 704
Study 32711747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate oxygen exposure (29.1%-33.1% oxygen)
Number of subjects: 704
Study 32711747 — intervention group
Group type: EXPERIMENTAL
Intervention: High/intermediate oxygen exposure
Number of subjects: 704
Study 32711747 — intervention group
Group type: COMPARATOR
Intervention: Low oxygen exposure (below both cutoffs)
Number of subjects: 704
Study 32711950 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (major elective abdominal surgery)
Number of subjects: 15
Study 32712225 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 20
Study 32712650 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1(+)-CTCs
Number of subjects: 72
Study 32712650 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple negative (TN) phenotype
Number of subjects: 72
Study 32712650 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of metastatic treatments
Number of subjects: 72
Study 32712650 — intervention group
Group type: EXPERIMENTAL
Intervention: >2 metastatic sites
Number of subjects: 72
Study 32712650 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥5 CTCs
Number of subjects: 72
Study 32712650 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone receptor negativity
Number of subjects: 72
Study 32712650 — intervention group
Group type: COMPARATOR
Intervention: TN phenotype and >2 metastatic sites
Number of subjects: 72
Study 32712658 — intervention group
Group type: EXPERIMENTAL
Intervention: CIR-Ala
Number of subjects: 145
Study 32712658 — intervention group
Group type: EXPERIMENTAL
Intervention: CIR-Ala, CIR-Gly, CIR-Ile, smoking, leisure physical activity, and body weight
Number of subjects: 145
Study 32712658 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-estimated AS intake
Number of subjects: 145
Study 32712702 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT performed from day 6 to day 14 of the onset of symptoms
Number of subjects: 13
Study 32712806 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent belantamab mafodotin (2.5 mg/kg)
Number of subjects: 95
Study 32712962 — intervention group
Group type: EXPERIMENTAL
Intervention: Different surgical techniques for removal of mandibular wisdom teeth
Number of subjects: 4643
Study 32712962 — intervention group
Group type: COMPARATOR
Intervention: Lingual retractor vs no lingual retractor
Number of subjects: 4643
Study 32712962 — intervention group
Group type: COMPARATOR
Intervention: Lingual split with chisel vs surgical hand-piece for bone removal
Number of subjects: 4643
Study 32712962 — intervention group
Group type: COMPARATOR
Intervention: Mechanical vs manual irrigation method
Number of subjects: 4643
Study 32712962 — intervention group
Group type: COMPARATOR
Intervention: High vs low irrigation volume
Number of subjects: 4643
Study 32712962 — intervention group
Group type: COMPARATOR
Intervention: Low vs high irrigation volume
Number of subjects: 4643
Study 32712962 — intervention group
Group type: COMPARATOR
Intervention: Primary vs secondary wound closure
Number of subjects: 4643
Study 32712962 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP) or platelet rich fibrin (PRF) in sockets
Number of subjects: 4643
Study 32713940 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 11
Study 32714156 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term spinal cord stimulation
Number of subjects: 0
Study 32714178 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (transcranial Direct Current Stimulation)
Number of subjects: 0
Study 32714178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 32714280 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32714408 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen dripping pills (CDDP)
Number of subjects: 0
Study 32714423 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin sequential therapy (BST) for 24 weeks
Number of subjects: 96
Study 32714423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 96
Study 32714561 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement intervention
Number of subjects: 0
Study 32714561 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 32715151 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance to a course on SNS use (T1)
Number of subjects: 0
Study 32715151 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education and brain functioning (C1)
Number of subjects: 0
Study 32715151 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (waiting list) (C)
Number of subjects: 0
Study 32715396 — intervention group
Group type: EXPERIMENTAL
Intervention: aMCI APOEε4 carriers
Number of subjects: 75
Study 32715396 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 75
Study 32715736 — intervention group
Group type: EXPERIMENTAL
Intervention: erenumab 70 mg s.c. (every 28 days) for a total of three administrations
Number of subjects: 40
Study 32715796 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-titrating continuous positive airway pressure (PAP) therapy initiated in 13 subjects who screened positive for OSA.
Number of subjects: 31
Study 32715796 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening using sleep apnea clinical score (SAC) and portable sleep testing.
Number of subjects: 31
Study 32715796 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for OSA with a portable sleep testing system.
Number of subjects: 31
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Prespecified risk criteria from FAST-TAVI for early discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital complications before discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge complications
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehospitalization within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker implantation within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Any stroke within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular-access-related complications within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-threatening bleeding within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney failure within 1 year after discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for low risk and early discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for high risk and late discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for low risk but late discharge
Number of subjects: 502
Study 32715844 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite events within 1 year after discharge for high risk but early discharge
Number of subjects: 502
Study 32715853 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO
Number of subjects: 0
Study 32715853 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 0
Study 32716060 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 2007
Study 32716060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinchenghao decoction (YCHD)
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Danxioling and Yiganling
Number of subjects: 2007
Study 32716060 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia
Number of subjects: 2007
Study 32716292 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose tigecycline (100 mg q12h) in CRRT group (7 cases)
Number of subjects: 16
Study 32716292 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose tigecycline (100 mg q12h) in non-CRRT group (9 cases)
Number of subjects: 16
Study 32716355 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MTA and PA visual rating scales
Number of subjects: 73
Study 32716355 — intervention group
Group type: COMPARATOR
Intervention: Single visual rating scale
Number of subjects: 73
Study 32716355 — intervention group
Group type: COMPARATOR
Intervention: Gray matter volumetric measures
Number of subjects: 73
Study 32716707 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors
Number of subjects: 208757
Study 32716707 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitors
Number of subjects: 208757
Study 32716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 208757
Study 32716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 208757
Study 32716707 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 208757
Study 32716739 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab
Number of subjects: 104
Study 32716957 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diagnostic tool (Kiddie-SADS Present and Lifetime psychosis section)
Number of subjects: 302
Study 32716957 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized assessment
Number of subjects: 302
Study 32717265 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy-estimated sleep fragmentation
Number of subjects: 150
Study 32717265 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy-estimated total sleep time and interdaily stability
Number of subjects: 150
Study 32717265 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE ε4 allele presence
Number of subjects: 150
Study 32717265 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphy-estimated sleep variables at 7 days post-ICU discharge
Number of subjects: 150
Study 32717315 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra leadless pacemaker
Number of subjects: 104
Study 32717365 — intervention group
Group type: EXPERIMENTAL
Intervention: Video capsule endoscopy (VCE) in patients with DA
Number of subjects: 201
Study 32717365 — intervention group
Group type: COMPARATOR
Intervention: Video capsule endoscopy (VCE) in control patients (obscure GI bleeding or iron deficiency anemia)
Number of subjects: 201
Study 32717408 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic gene expression signature
Number of subjects: 483
Study 32718212 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantoplasty (IP)
Number of subjects: 41
Study 32718212 — intervention group
Group type: COMPARATOR
Intervention: No implantoplasty (control)
Number of subjects: 41
Study 32718257 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of AF (368 patients, 21.4%)
Number of subjects: 1722
Study 32718257 — intervention group
Group type: COMPARATOR
Intervention: No family history of AF
Number of subjects: 1722
Study 32718257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥2 relatives affected by AF (3.5%)
Number of subjects: 1722
Study 32718289 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat to Target (T2T) strategy
Number of subjects: 0
Study 32718289 — intervention group
Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study 32718560 — intervention group
Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 0
Study 32718723 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic risk calculator for BIMS developed and validated using logistic regression with bootstrapping.
Number of subjects: 16079
Study 32718723 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified index based on preoperative haemoglobin <120 g L.
Number of subjects: 16079
Study 32718876 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry-based method for quantifying viable lymphocyte immunophenotypes
Number of subjects: 0
Study 32718906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W) for ≤24 months or until confirmed progression or unacceptable toxicity
Number of subjects: 44
Study 32718906 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg every 2 weeks (Q2W)
Number of subjects: 44
Study 32718926 — intervention group
Group type: EXPERIMENTAL
Intervention: CNSD users (n=100)
Number of subjects: 246
Study 32718926 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-hypnotics
Number of subjects: 246
Study 32718997 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib (350 mg) combined with tamoxifen plus goserelin
Number of subjects: 0
Study 32718997 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg) combined with tamoxifen plus goserelin
Number of subjects: 0
Study 32718997 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 0
Study 32718997 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib
Number of subjects: 0
Study 32719074 — intervention group
Group type: EXPERIMENTAL
Intervention: 0/1-hour hs-cTnT algorithm
Number of subjects: 1711
Study 32719074 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group
Number of subjects: 1711
Study 32719074 — intervention group
Group type: COMPARATOR
Intervention: Rule-out group
Number of subjects: 1711
Study 32719417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral digoxin 0.5 mg
Number of subjects: 40
Study 32719455 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib with capecitabine
Number of subjects: 69
Study 32719455 — intervention group
Group type: EXPERIMENTAL
Intervention: androgen receptor inhibitor with CDK4/6 inhibitor
Number of subjects: 69
Study 32719455 — intervention group
Group type: EXPERIMENTAL
Intervention: anti PD-1 with nab-paclitaxel
Number of subjects: 69
Study 32719455 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitor included
Number of subjects: 69
Study 32719455 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-VEGFR included
Number of subjects: 69
Study 32719455 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor with nab-paclitaxel
Number of subjects: 69
Study 32719636 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-month professional development/education module for preschool staff
Number of subjects: 1200
Study 32719636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1200
Study 32719915 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo imaging of mitochondrial membrane potential (ΔΨ)
Number of subjects: 13
Study 32719964 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 504
Study 32720004 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in traditional practices
Number of subjects: 63
Study 32720004 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use (alcohol, marijuana, methamphetamine)
Number of subjects: 63
Study 32720004 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercialized tobacco use
Number of subjects: 63
Study 32720004 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive functioning
Number of subjects: 63
Study 32720004 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual connectedness
Number of subjects: 63
Study 32720012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with acute surgical condition and concomitant COVID-19 (Group A)
Number of subjects: 215
Study 32720012 — intervention group
Group type: COMPARATOR
Intervention: Patients with severe COVID-19 developing acute abdominal pathologies (Group B)
Number of subjects: 215
Study 32720016 — intervention group
Group type: EXPERIMENTAL
Intervention: OSAHS patients (mild, moderate, severe)
Number of subjects: 242
Study 32720016 — intervention group
Group type: COMPARATOR
Intervention: non-OSAHS patients
Number of subjects: 242
Study 32720016 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of OSAHS
Number of subjects: 242
Study 32720016 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT, carotid plaque, blood flow velocity, and blood lipid
Number of subjects: 242
Study 32720404 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide QRS (LBBB, RBBB, non-specific IVCD, QRS 110-129 ms)
Number of subjects: 11861
Study 32720404 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset LBBB
Number of subjects: 11861
Study 32720404 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS widening ≥130 ms
Number of subjects: 11861
Study 32720457 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based treatment (FBT)
Number of subjects: 172
Study 32720900 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth Literacy Scale (eHEALS)
Number of subjects: 1695
Study 32720911 — intervention group
Group type: EXPERIMENTAL
Intervention: TECH+PHONE group
Number of subjects: 433
Study 32720911 — intervention group
Group type: COMPARATOR
Intervention: SC group
Number of subjects: 433
Study 32720911 — intervention group
Group type: COMPARATOR
Intervention: TECH group
Number of subjects: 433
Study 32720911 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM (20 items)
Number of subjects: 433
Study 32720911 — intervention group
Group type: EXPERIMENTAL
Intervention: Convergent validity using motivation for weight loss scale
Number of subjects: 433
Study 32721016 — intervention group
Group type: EXPERIMENTAL
Intervention: UX023-CL201, UX023-CL205, UX023-CL301 (interventional trials)
Number of subjects: 228
Study 32721016 — intervention group
Group type: EXPERIMENTAL
Intervention: UX023-CL002 (observational, retrospective chart review)
Number of subjects: 228
Study 32721110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF)
Number of subjects: 30
Study 32721404 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside Swallowing Evaluation (BSE)
Number of subjects: 213
Study 32721404 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE-based decision tree algorithm
Number of subjects: 213
Study 32721404 — intervention group
Group type: COMPARATOR
Intervention: Flexible Endoscopic Evaluation of Swallowing (FEES)
Number of subjects: 213
Study 32721422 — intervention group
Group type: EXPERIMENTAL
Intervention: NIBB APBI using a dose of 34 Gy in 10 fractions delivered daily or twice a day.
Number of subjects: 40
Study 32721422 — intervention group
Group type: EXPERIMENTAL
Intervention: NIBB APBI
Number of subjects: 40
Study 32721510 — intervention group
Group type: EXPERIMENTAL
Intervention: High haemoglobin group
Number of subjects: 518
Study 32721510 — intervention group
Group type: COMPARATOR
Intervention: Low haemoglobin group
Number of subjects: 518
Study 32721547 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System (PROMIS) scales
Number of subjects: 121
Study 32721547 — intervention group
Group type: EXPERIMENTAL
Intervention: Defense and Veterans Pain Rating Scale (DVPRS)
Number of subjects: 121
Study 32721547 — intervention group
Group type: COMPARATOR
Intervention: Legacy scales
Number of subjects: 121
Study 32721891 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical separation of parasitic twins
Number of subjects: 4
Study 32721891 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 4
Study 32721954 — intervention group
Group type: EXPERIMENTAL
Intervention: Narsoplimab, a monoclonal antibody against MASP-2, dosage and duration not specified.
Number of subjects: 0
Study 32721955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-biomarker strategy using 12 top ranked plasma proteins
Number of subjects: 135
Study 32721955 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-biomarker strategy in patients with normal CgA concentrations
Number of subjects: 135
Study 32721955 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 135
Study 32722686 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenthood (mothers with varying parity)
Number of subjects: 235
Study 32722686 — intervention group
Group type: COMPARATOR
Intervention: Parenthood (parents of one child)
Number of subjects: 235
Study 32722801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0
Study 32722801 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study 32723298 — intervention group
Group type: EXPERIMENTAL
Intervention: Four square step test
Number of subjects: 89
Study 32723298 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength
Number of subjects: 89
Study 32723298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean mass
Number of subjects: 89
Study 32723341 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRMs assessment integrated with EMR
Number of subjects: 600
Study 32723341 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonton symptom assessment scale
Number of subjects: 600
Study 32723341 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Thermometer
Number of subjects: 600